2Mellwing KP, Bailer D, Gleichmann U, et al . Improvement of coronary vasodilatation capacity through single LDL apheresis[J]. Atherosclerosis . 1998.139:173-178.
3Bonetti PO, Lerman LO, Napoli C, et al . Statin effects beyond lipid lowering: are they clinically relevant[J]? Eur Heart J , 2003,24:225-248.
4Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro[J]. J Heart Lung Transplant ,1998,17:335-340.
5Kobashigawa JA, Katznelson S, Laks H, et al . Effects of pravastatin on outcomes after cardiac transplantation[J]. N Engl J Med , 1995,344:2016-2018.
6Wenke K. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four year randomized trial[J]. Circulation , 1997,96:1498 1402.
7Nair DR, Papadakis JA, Jagroop IA, et al . Statin and fibrinogen[J]. Lancet, 1998,351:463-466.
8Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG CoA reductase inhibitors on fibrinogen[J].Atherosclerosis , 2001.155 : 463-466.
9Weis M. Statins have biphasic effects on angiogenesis[J].Circulation , 2002,105:739-745.
10Dimitroulakos J, Nohynek D, Backway KL, et al . Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach[J]. Blood ,1999.1308-1318.
二级参考文献15
1Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
2Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
3Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
4Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
5Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999,340: 115-126.
6Goran K Hansson. Immune Mechanism In Atherosclerosis Arteroscler Thromb Vasc Biol . 2001,21:1876-1890.
7Koefig W. Inflammation and coronary heart disease:an overview Cardiol Rev, 2001,9:31-35.
8Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation, 1997,96:396-399.
9Brown DL, Hibbs MS, Kearney M, et al. Identification 92 kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation , 1995, 91: 2125-2131.
10Chalmers J, WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension. J Hypertens, 1999,17:151-183.
